---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-041274"
form_type: "8-K"
ticker: "AMLX"
cik: "0001658551"
company_name: "Amylyx Pharmaceuticals, Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T17:54:59.849100+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Amylyx Q2 product revenue $98.2M, net income $22.1M; CHMP re-examining MAA

## Summary
- Net product revenue $98.2M in Q2 2023 (up from $71.4M in Q1); net income $22.1M ($0.31 diluted EPS).
- Cash, equivalents and short-term investments $357.3M at June 30, 2023.
- Phase 3 ORION trial of AMX0035 for PSP to start by year-end; ~600 participants planned.
- CHMP re-examining negative opinion on AMX0035 MAA for ALS; final opinion expected fall 2023.
- Five Canadian provinces now reimburse ALBRIOZA; broad public coverage expected by end of August.

## SEC filing metadata
- accession: 0000950170-23-041274
- form_type: 8-K
- ticker: AMLX
- cik: 0001658551
- company_name: Amylyx Pharmaceuticals, Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658551/000095017023041274/0000950170-23-041274-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658551/000095017023041274/amlx-20230810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-041274
- JSON: https://secwatch.observer/filing/0000950170-23-041274.json
- Plain text: https://secwatch.observer/filing/0000950170-23-041274.txt

## Key facts
- Earnings Releases
  Amylyx Pharmaceuticals, Inc. reported second quarter ended June 30, 2023 results: revenue $98.2 million, net income $22.1 million, EPS $0.31 on a fully diluted per share basis.
  - Period: second quarter ended June 30, 2023
  - Revenue: $98.2 million
  - Net income: $22.1 million
  - EPS: $0.31 on a fully diluted per share basis
  - Result: reported results
  source text: in such filing. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Amylyx Pharmaceuticals Reports Second Quarter 2023 Financial Results ˗ Second quarter 2023 product revenue of $98.2 million; demand and insurance coverage for RELYVRIO® in U.S. and ALBRIOZATM in Canada continued to grow ˗ Strong financial position supported by $22.1 million of net income during the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1658551/000095017023041274/0000950170-23-041274-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.